Erythropoietin production in patients with chronic renal failure - PubMed (original) (raw)
Comparative Study
Erythropoietin production in patients with chronic renal failure
A Kato et al. Ren Fail. 1994.
Free article
Abstract
Studies were performed to reexamine the response of erythropoietin (Epo) production to acute hypoxic stimuli in patients with end-stage renal disease (ESRD). In the absence of acute bleeding or hypoxia, the serum Epo level in ESRD was similar to that of normal subjects despite severe anemia. In 11 dialysis patients with acute bleeding, the decrease in the Hb level from 8.9 to 5.8 g/dL provoked a significant increase in serum Epo up to 52.2 times the normal value. The increase in serum Epo was associated with a significant increase in corrected reticulocyte. Systemic hypoxemia (PaO2 < 65 mm Hg) in 8 dialysis patients provoked a significant elevation in the serum Epo level up to 24.6 times the normal level. There was an inverse relationship between serum Epo and arterial PaO2 (r = -0.715). The serum Epo level in these patients declined to or near the normal value after recovery from acute hypoxic stress. These data suggest that the ability of the Epo production is well preserved in ESRD, indicating that acute hypoxic stimuli provoke a significant increase in serum Epo.
Similar articles
- Serum erythropoietin levels in children with chronic renal failure.
Müller-Wiefel DE, Schärer K. Müller-Wiefel DE, et al. Kidney Int Suppl. 1983 Nov;15:S70-6. Kidney Int Suppl. 1983. PMID: 6584679 - Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved.
Ross RP, McCrea JB, Besarab A. Ross RP, et al. ASAIO J. 1994 Jul-Sep;40(3):M880-5. doi: 10.1097/00002480-199407000-00122. ASAIO J. 1994. PMID: 8555638 - Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease.
Góes MA, Dalboni MA, Manfredi SR, Cendoroglo MS, Batista MC, Canziani ME, Balakrishnan VS, Pereira BJ, Draibe SA, Cendoroglo M. Góes MA, et al. Clin Nephrol. 2010 Jan;73(1):7-13. doi: 10.5414/cnp73007. Clin Nephrol. 2010. PMID: 20040346 - [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N. Dimković N. Med Pregl. 2001 May-Jun;54(5-6):235-40. Med Pregl. 2001. PMID: 11759218 Review. Croatian.
Cited by
- Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP. Provenzano R, et al. J Clin Pharmacol. 2020 Nov;60(11):1432-1440. doi: 10.1002/jcph.1648. Epub 2020 Jun 30. J Clin Pharmacol. 2020. PMID: 32603526 Free PMC article. Clinical Trial. - Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease.
Liu J, Wei Q, Guo C, Dong G, Liu Y, Tang C, Dong Z. Liu J, et al. Int J Mol Sci. 2017 Apr 30;18(5):950. doi: 10.3390/ijms18050950. Int J Mol Sci. 2017. PMID: 28468297 Free PMC article. Review. - Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. Nephrol Dial Transplant. 2015. PMID: 26238121 Free PMC article. Clinical Trial. - Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
Flamme I, Oehme F, Ellinghaus P, Jeske M, Keldenich J, Thuss U. Flamme I, et al. PLoS One. 2014 Nov 13;9(11):e111838. doi: 10.1371/journal.pone.0111838. eCollection 2014. PLoS One. 2014. PMID: 25392999 Free PMC article. - Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.
Doshi S, Krzyzanski W, Yue S, Elliott S, Chow A, Pérez-Ruixo JJ. Doshi S, et al. Clin Pharmacokinet. 2013 Dec;52(12):1063-83. doi: 10.1007/s40262-013-0098-x. Clin Pharmacokinet. 2013. PMID: 23912564 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials